Assenagon Asset Management S.A. Has $35.69 Million Stock Holdings in IDEXX Laboratories, Inc. $IDXX

Assenagon Asset Management S.A. cut its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 10.9% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 55,868 shares of the company’s stock after selling 6,863 shares during the quarter. Assenagon Asset Management S.A.’s holdings in IDEXX Laboratories were worth $35,694,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in IDXX. Cresset Asset Management LLC boosted its holdings in IDEXX Laboratories by 11.0% during the first quarter. Cresset Asset Management LLC now owns 2,616 shares of the company’s stock worth $1,099,000 after purchasing an additional 259 shares during the last quarter. Wellington Management Group LLP grew its holdings in IDEXX Laboratories by 12.4% during the first quarter. Wellington Management Group LLP now owns 219,573 shares of the company’s stock valued at $92,210,000 after purchasing an additional 24,204 shares during the period. Erste Asset Management GmbH increased its holdings in IDEXX Laboratories by 193.9% in the 1st quarter. Erste Asset Management GmbH now owns 9,670 shares of the company’s stock worth $4,021,000 after acquiring an additional 6,380 shares during the last quarter. Capital Fund Management S.A. purchased a new position in shares of IDEXX Laboratories in the first quarter valued at $8,507,000. Finally, Price T Rowe Associates Inc. MD increased its position in shares of IDEXX Laboratories by 71.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,988,912 shares of the company’s stock valued at $835,244,000 after buying an additional 825,965 shares during the period. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, EVP Nimrata Hunt sold 9,425 shares of IDEXX Laboratories stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $703.34, for a total value of $6,628,979.50. Following the completion of the transaction, the executive vice president directly owned 21,149 shares of the company’s stock, valued at approximately $14,874,937.66. The trade was a 30.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.98% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on IDXX. UBS Group raised their target price on shares of IDEXX Laboratories from $710.00 to $750.00 and gave the company a “neutral” rating in a research note on Tuesday, November 4th. BTIG Research increased their price target on shares of IDEXX Laboratories from $785.00 to $830.00 and gave the stock a “buy” rating in a report on Tuesday, November 4th. Jefferies Financial Group reaffirmed a “buy” rating and set a $830.00 price objective on shares of IDEXX Laboratories in a report on Tuesday, November 4th. Barclays initiated coverage on shares of IDEXX Laboratories in a research report on Monday, December 8th. They issued an “overweight” rating and a $850.00 target price for the company. Finally, Wall Street Zen downgraded IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Saturday, November 29th. Eight investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, IDEXX Laboratories has an average rating of “Moderate Buy” and an average price target of $763.50.

IDEXX Laboratories Stock Performance

NASDAQ:IDXX opened at $697.10 on Friday. The company has a quick ratio of 0.87, a current ratio of 1.18 and a debt-to-equity ratio of 0.24. The firm’s fifty day simple moving average is $688.68 and its 200 day simple moving average is $624.29. The stock has a market cap of $55.66 billion, a P/E ratio of 55.28, a price-to-earnings-growth ratio of 4.15 and a beta of 1.67. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Monday, November 3rd. The company reported $3.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.14 by $0.08. IDEXX Laboratories had a return on equity of 67.78% and a net margin of 24.65%.The firm had revenue of $1.11 billion during the quarter, compared to analyst estimates of $1.07 billion. During the same quarter in the prior year, the company earned $2.80 EPS. The business’s revenue was up 13.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. As a group, research analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.